3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions, SMEs, and 8 major pharmaceutical companies, teamed to study a fundamental issue in medicine: the mechanisms of response and non-response to therapies, the major aim of 3TR, both within single disease entities and across diseases, where molecular stratification may identify shared disease taxonomies. The molecular identification of groups of patients to whom a drug will benefit, will allow focusing on those who are drug orphan. Harmonization of data from existing academy or industry-sponsored studies will identify biomarkers to inform a new collection. Specimens of diseased tissues, blood, stools, and other fluids will be obtained in a de novo observational prospective trial with standard of care medication prior, during and after first or second line of treatment. Because the studies will be at different phases of progression, a carrousel model of work was designed for input and output of data to be continuously analysed, and interpreted, to inform those measurements to be undertaken and allow cross-validation of results. The 3TR team will elucidate the role of the microbiome, genetics and regulatory genomic features in disease progression. The working aims of 3TR are: 1) establish a centralized data management platform; 2) perform comprehensive molecular and clinical characterisation of a prospective patient cohort; 3) establish integrated analysis of all data using advanced bioinformatics/statistical and modelling methods; 4) identify sets of predictive biomarkers of response/non-response to therapies; 5) improve the competitiveness of European industry and support development of novel solutions. 3TR will sustain beyond the project end the samples and its knowledge base. 3TR will challenge and revolutionize the conventional single-disease based approach with important implications in future disease treatment.

BRECISE is a Public-Private Partnership Project, co-funded by the Innovative Health Initiative (IHI) of the European commission aiming at creating a collaborative ecosystem to accelerate the clinical validation of Next-Generation Sequencing (NGS)-based, multi-modality Artificial Intelligence (AI) oncology biomarkers and related technologies. By addressing technical and regulatory challenges, the consortium unites diverse expertise and resources to validate novel prostate and bladder cancer biomarkers, ensuring their efficacy and clinical utility. This initiative aligns with the goal of advancing precision medicine in oncology, ultimately improving patient outcomes and streamlining personalized cancer care. BRECISE's primary objective is to enhance biomarker-driven approaches for patient risk stratification, disease progression prediction, and treatment response assessment, within the framework of precision medicine. The project addresses the current challenge of limited access to clinically validated prognostic and predictive biomarkers in oncology. By providing healthcare professionals with NGS-based, multi-modality AI oncology biomarkers, BRECISE aims to enable precise disease risk assessment and informed treatment selection, contributing to more personalized and effective patient care. The impact of BRECISE is transformative, aiming to revolutionize risk assessment and treatment selection in oncology, facilitating the implementation of precision medicine. This will significantly reduce unnecessary and ineffective treatments, optimizing patient care and minimizing side effects. The validated biomarker technologies empower researchers to develop safer and more effective personalized treatments, advancing precision medicine. These advancements will enhance the competitiveness of European health industries, positioning them at the forefront of innovation and healthcare excellence. Overall, BRECISE is expected to significantly improve patient outcomes, enhance healthcare efficiency, and bolster the global standing of European health industries.

Autoimmune disorders are highlyImmune-mediated disorders are highly heterogenenous entities for which the mechanisms of disease progression and therapeutic responses are only recently beginning to be understood. The patterns of transcriptome are the reflection of distinct cell types that are involved in the development of the disease process. Our plan is to approach the diseases beginning from a global view that allows us to then come down to the most relevant cell types in tissues and blood. In addition, by understanding disease heterogeneity and diseases similarities, we can also identify the best pathways to be targeted with specific biological treatments. The diseases involved are systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, asthma, chronic obstructive pulmonary disease, Crohn´s disease and ulcerative colitis. Based on a unique ongoing platform of clinical groups across Europe and specialists in cell and molecular profiling, imaging analyses, single cell sequencing and analysis, we will identify the molecular basis of each of the diseases heterogeneity, the mechanisms of treatment non responsiveness, and develop a specialized training program where students will be able to visualize the overall work from design to analysis of the data and become engaged in the unique multi-disciplinariry of this platform. The platform will have available existing clinical studies and clinical trials, but will be also producing new data from prospective studies where samples and tissues for each disease, based on the appropriate indications will be obtained with special protocols, for the study. The engaged students will be permeated by the latest advances in not one, but several new approaches and systems biology modelling, and develop out-of-the-box concepts where diseases can be viewed not as separate clinical entities but as novel groups of shared molecular and cellular patterns that impinge on specific tissues by specialized cell types.